2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.09A.03 Safety and Efficacyof Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases

EP.09A.03 Safety and Efficacyof Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases

Back to course

Pdf Summary

The study explores the safety and efficacy of combining cranial radiotherapy with aumolertinib as a first-line treatment for patients with brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). This investigation aimed to address the gap in knowledge regarding the effectiveness of aumolertinib—a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)—in this context, as its counterpart osimertinib is already known for successfully penetrating the blood-brain barrier.<br /><br />Between 2016 and 2023, the study retrospectively enrolled 16 patients with a median age of 63, where 62.5% were female. Patients had varying numbers and sizes of BM lesions, with a median size of 1.2 cm, and 87.5% of them exhibited a baseline Karnofsky Performance Status (KPS) of 70. Treatment included modalities like whole-brain radiotherapy (WBRT), stereotactic radiotherapy (SRT), hypofractionated stereotactic radiotherapy (HSRT), and simultaneously integrated boost WBRT (SIB-WBRT), alongside aumolertinib therapy at 110 mg daily.<br /><br />The median overall survival (OS) for all patients was 31.3 months, with 1-, 2-, and 3-year OS rates at 93.3%, 60.0%, and 48.0%, respectively. For those receiving local hypofractionated radiotherapy, these metrics were slightly higher. The central nervous system objective response rate (CNS ORR) was 81.3%, with no cases of grade 3 cerebral radiation necrosis observed.<br /><br />In conclusion, aumolertinib demonstrated preliminary safety and efficacy when used as a first-line therapy in combination with cranial radiotherapy for this patient group. The promising outcomes highlight the potential of this combined approach, warranting further research to confirm these findings.

Asset Subtitle

Sun han

Meta Tag

Speaker Sun han

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

cranial radiotherapy

aumolertinib

brain metastases

EGFR-mutant NSCLC

tyrosine kinase inhibitor

blood-brain barrier

whole-brain radiotherapy

stereotactic radiotherapy

overall survival

central nervous system